9,495 Shares in argenx SE (NASDAQ:ARGX) Purchased by Point72 Europe London LLP

Point72 Europe London LLP bought a new stake in shares of argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 9,495 shares of the company's stock, valued at approximately $5,839,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. GeoWealth Management LLC raised its stake in shares of argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after acquiring an additional 18 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in shares of argenx during the 4th quarter worth approximately $37,000. Global Retirement Partners LLC grew its holdings in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares during the period. FIL Ltd bought a new position in shares of argenx in the 4th quarter worth $38,000. Finally, Jones Financial Companies Lllp boosted its holdings in argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

argenx Price Performance

ARGX stock opened at $532.27 on Thursday. The company has a 50 day simple moving average of $592.11 and a 200 day simple moving average of $612.79. The stock has a market cap of $32.50 billion, a price-to-earnings ratio of -604.85 and a beta of 0.57. argenx SE has a 1 year low of $356.38 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. On average, equities research analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARGX has been the topic of several recent analyst reports. William Blair reiterated an "outperform" rating on shares of argenx in a report on Friday, February 28th. JMP Securities set a $699.00 price objective on shares of argenx in a research report on Wednesday. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th. Wedbush reiterated an "outperform" rating and set a $715.00 price target on shares of argenx in a report on Friday, April 11th. Finally, HC Wainwright restated a "buy" rating and set a $720.00 target price on shares of argenx in a research note on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, twenty have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $698.11.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.